BRAF V600E Mutation Detection in Circulating Cell-Free DNA by Digital Droplet PCR
2013921
Ordering Recommendation
Determine BRAF V600E mutation status in patients with solid tumors to select candidates for targeted therapy with kinase inhibitors (BRAF and/or MEK). Monitor response to therapy and disease progression in patients carrying BRAF V600E mutation.
Mnemonic
BRAF CFDNA
Methodology
Polymerase Chain Reaction
Performed
Varies
Reported
10-12 days
New York DOH Approval Status
Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
- Patient Preparation
- Collect
- Whole blood in two 10mL Cell-Free DNA (cfDNA) BCT Tubes. Specimens must be collected using the Kit, Cell-Free DNA Blood Collection Tube (ARUP Supply #52358) available online through eSupply using ARUP Connect or contact ARUP Client Services at (800) 522-2787.
- Specimen Preparation
- Transport 20 mL whole blood in cfDNA BCT Tubes. (Min: 16 mL)
- Storage/Transport Temperature
- Refrigerated.
- Unacceptable Conditions
- FFPE tissue. Whole blood collected in non-cfDNA BCT tubes.
- Remarks
- Stability
- Ambient: 5 days; Refrigerated: 5 days; Frozen: Unacceptable
Reference Interval
Refer to report.
Interpretive Data
Compliance Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
Note
CPT Code(s)
Components
| Component Test Code* | Component Chart Name | LOINC |
|---|---|---|
| 2013922 | BRAF V600E cfDNA Result | 58415-1 |
| 2013924 | BRAF V600E cfDNA Mutant Allele Frequency | |
| 2013925 | BRAF V600E cfDNA Mutant copies/mL |
Aliases